Article Text

PDF
SAT0262 Comparison of Serum Matrix Metalloproteinase-3 Levels in Rheumatoid Arthritis after Treatment with Biologic Agents for 24 Weeks
  1. Y. Hattori1,
  2. A. Kaneko1,
  3. D. Kida1,
  4. N. Takahashi2,
  5. H. Ishikawa1,
  6. H. Kanda1,
  7. T. Sato1,
  8. T. Kojima2,
  9. N. Ishiguro2
  1. 1Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center
  2. 2Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

Abstract

Background Matrix metalloproteinase-3 (MMP-3) is an enzyme produced by synoviocytes, and is a marker of synovitis that gives a more direct indication of actual joint destruction than either C-reactive protein (CRP) in patients with rheumatoid arthritis (RA).

Objectives Our aim in this study is to investigate the impact of the trend of serum MMP-3 and CRP during the treatment Adalimumab (ADA), Tocilizumab (TCZ), and Abatacept (ABT) in RA patients.

Methods Among 672 patients with active RA (DAS28-CRP≥2.7) who were recruited in TBCR (Tsurumai Biologics Communication Registry), 303 patients were received ADA (40mg subcutaneously every other week) therapy, 124 patients were received TCZ (8 mg/kg every 4 weeks) therapy, and 245 patients were received ABT therapy (500mg for<60 kg; 750 mg for 60 kg-100 kg; and 1 gram for>100 kg infusion at week 0, 2, 4 and every 4 weeks). DAS28-CRP remission (DAS28-CRP<2.3) rates at 24 weeks were 35% (73/210) for ADA therapy, 24% (30/124) for TCZ therapy, and 19% (39/201) for ABT therapy. We analyzed 142 patients who had DAS28-CRP remission at 24 weeks, consisting of 73 patients in ADA group, 30 patients in TCZ group, and 39 patients in ABT group, respectively. We compared the % change in serum MMP-3 and CRP levels from first administration to 24 weeks in 3 groups.

Results While there was significant baseline difference in age, methotrexate (MTX) use and dose in 3 groups, there was no significant baseline difference in serum MMP-3 and CRP levels in 3 groups (Table). DAS28-CRP decreased similarly over the course of 24 weeks in 3 groups (Fig. 1). The % change in serum MMP-3 levels at 12, and 24 weeks was significantly greater in the ADA group than in the ABT group. ADA group is higher than TCZ group in the % change in serum MMP-3 levels over the course of 24 weeks. There was no difference in the % change in serum MMP-3 levels between the TCZ group and ABT group over the course of 24 weeks (Fig. 2a). The % change in CRP levels at 4 weeks was significantly greater in the ADA group than in the ABT group. However, there was no difference in the % change in CRP levels at 12, and 24 weeks between the ADA group and the ABT group. There was no difference in the % change in CRP levels between the ADA group and the TCZ group, the TCZ group and ABT group at 12 and 24 weeks (Fig. 2b).

Conclusions ADA showed improvements in serum MMP-3 levels from an early stage in 24 weeks in a comparison with ABT. ADA can suppress synovitis and therefore the progression of joint destruction by strongly inhibiting MMP-3 when it is administered from an early stage.

Disclosure of Interest Y. Hattori: None declared, A. Kaneko: None declared, A. Kaneko: None declared, D. Kida: None declared, D. Kida: None declared, N. Takahashi: None declared, N. Takahashi: None declared, H. Ishikawa: None declared, H. Ishikawa: None declared, H. Kanda: None declared, H. Kanda: None declared, T. Sato: None declared, T. Sato: None declared, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, T. Kojima Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer, N. Ishiguro Speakers bureau: Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Eisai Pharma Corporation, Chugai Pharma Corporation, Abbvie, Bristol-Myers Squibb and Pfizer

DOI 10.1136/annrheumdis-2014-eular.2074

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.